A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

A novel signature based on cancer-associated fibroblast genes to predict prognosis, immune feature, and therapeutic response in breast cancer

Published:2023-05-04 Issue:9 Volume:15 Page:3480-3497
ISSN:1945-4589
Container-title:Aging
language:en
Short-container-title:Aging

Author:

Wang Yichen¹,Lv Wenchang¹,Yi Yi¹,Zhang Qi¹,Zhang Jun²,Wu Yiping¹

Affiliation:

1. Department of Plastic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, Hubei, China

2. Department of Thyroid and Breast Surgery, Shenzhen Qianhai Shekou Free Trade Zone Hospital, Shenzhen 518067, Guangdong, China

Publisher

Impact Journals, LLC

Subject

Cell Biology,Aging

Reference37 articles.

1. Breast Cancer Statistics, 2022.;Siegel;CA Cancer J Clin,2022

2. Breast Cancer Treatment: A Review.;Winer;JAMA,2019

3. Understanding the tumor immune microenvironment (TIME) for effective therapy.;Jain;Nat Med,2018

4. Crosstalk between cancer-associated fibroblasts and immune cells in the tumor microenvironment: new findings and future perspectives.;Shi;Mol Cancer,2021

5. Fibroblast Heterogeneity and Immunosuppressive Environment in Human Breast Cancer.;Kuperstein;Cancer Cell,2018

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Identification and validation of a new prognostic signature based on cancer-associated fibroblast-driven genes in breast cancer;World Journal of Clinical Cases;2024-02-06

2. Characterization of cancer-associated fibroblasts (CAFs) and development of a CAF-based risk model for triple-negative breast cancer;Cancer Cell International;2023-11-25

3. The driving mechanism and targeting value of mimicry between vascular endothelial cells and tumor cells in tumor progression;Biomedicine & Pharmacotherapy;2023-09

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3